BridgeBio said Pfizer’s filing of a complaint with the NAD “is an attempt to bypass the FDA, the federal agency responsible for overseeing prescription drug advertising, and to challenge promotional materials which have already been through the proper regulatory processes.” That is “problematic,” according to the statement.

The heated bidding war between Pfizer PFE and Danish rival, Novo Nordisk NVO, related to the proposed acquisition of obesity drug developer Metsera MTSR is finally over. Metsera, a New York-based biotech,

The greater a company's earnings, the better its position will be to pay dividends. However, Pfizer's adjusted earnings per share (EPS) declined 18% year over year in Q3. That might seem to indicate that the company's dividend is on shakier ground. But there's more to the story.

Pfizer offers a 7% dividend yield, lower COVID sales, oncology and cardiometabolic focus, and growth from Metsera and pipeline assets. See why PFE stock is a buy.

Revised transaction values Metsera at up to $86.25 per share -- Metsera's Board of Directors unanimously recommends that Metsera stockholders approve the adoption of the amended Pfizer merger agreement and approve the merger with Pfizer -- Transaction creates real,

Pfizer raised its 2025 profit forecast for the second time this year, as ongoing cost cuts helped make up for slow sales growth that’s driving its battle for the obesity startup Metsera.

During a press conference to announce a drug price deal for GLP-1s, President Donald Trump asked for more details about the ongoing bidding war between Novo Nordisk and Pfizer over obesity biotech Metsera.

Discover why Pfizer Inc. is rated a Strong Buy with 33% upside, robust dividends, and growth prospects ahead. Click for my updated look at PFE stock.

Nov 5 (Reuters) - Pfizer (PFE.N) plans to sweeten its bid for Metsera (MTSR.O), a person familiar with the matter told Reuters, after a judge denied its request to block rival drugmaker Novo Nordisk's $10 billion offer for the biotech company.

Pfizer reported a drop in third-quarter profits Tuesday as lower sales of Covid-19 products more than offset gains in other medications.

Pfizer (NYSE: PFE) beat earnings expectations decisively this morning, posting adjusted EPS of $0.87 against a $0.64 consensus and revenue of $16.65 billion versus $16.50 billion expected. The stock gapped up roughly 12.